Opioid-Specific Monoclonal Antibodies for Overdose Blocking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective therapeutic options to treat opioid use disorder and prevent or reverse opioid overdose, particularly due to the rise in opioid-related fatal overdoses and the threat posed by synthetic opioids like fentanyl and heroin.

Innovation Solution

Development of opioid-specific monoclonal antibodies (mAb) that bind to specific epitopes, allowing for treatment of opioid use disorder and prevention or reversal of opioid overdose, as well as detection of opioids in screening assays.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional opioid medications are used to treat opioid use disorder, then some patients benefit from pharmacotherapy, but only 1 out of 5 opioid addicts benefits and additional therapeutic options are needed

Engineering Contradiction:

Improveeffectiveness of opioid use disorder treatmentVSAvoidnumber of therapeutic options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the molecular target parameter from conventional opioid receptors to opioid antibodies, creating a fundamentally different mechanism of action. The monoclonal antibodies bind to opioid molecules themselves rather than acting through receptor modulation, providing a new therapeutic parameter that expands treatment options beyond conventional pharmacotherapy.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The monoclonal antibodies serve as intermediary molecules that intercept opioid substances before they reach the brain. These antibodies act as mediators between the opioid and the body's defense mechanisms, blocking the opioid's ability to cross the blood-brain barrier and produce its effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Force

If synthetic opioids such as fentanyl, carfentanil, and heroin are used, then pain relief is achieved, but they are included in the Department of Homeland Security Chemical Threat Risk Assessment list due to incapacitation and fatal overdose risks

Engineering Contradiction:

Improvepain relief effectVSAvoidfatal overdose and incapacitation risk

Core Design Contradiction:

ForceVSObject-affected harmful factors

Solution Approach 1:

The monoclonal antibodies provide preliminary anti-action by blocking opioid molecules in the bloodstream before they can cross the blood-brain barrier and cause incapacitation or fatal overdose. This preventive mechanism addresses the harmful effects before they occur, rather than treating symptoms after overdose begins.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent converts the harmful presence of opioids in the bloodstream into a beneficial situation by using the opioid molecules themselves as targets for the therapeutic antibodies. The same opioid substances that cause harm become the binding targets for the protective antibody response.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Measurement precision

If monoclonal antibodies are developed to bind to specific epitopes, then selective binding to opioids is achieved, but the complexity of antibody characterization and validation increases

Engineering Contradiction:

Improveselectivity of opioid bindingVSAvoidantibody characterization process

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the antibody characterization process into distinct functional validation steps: binding affinity measurement, selectivity testing against multiple opioids, and in vivo efficacy assessment. This segmentation allows systematic evaluation of each property independently, making the overall complex validation process more manageable and reproducible.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The monoclonal antibodies effectively block opioid distribution to the brain, reducing opioid-induced behavioral and toxic effects, and can be administered alongside opioid agonists or antagonists without interfering with endogenous signaling.

Implementation Method 1

The disclosure describes opioid-specific monoclonal antibodies (mAb)... that bind to specific epitopes

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

The monoclonal antibodies effectively block opioid distribution to the brain, reducing opioid-induced behavioral and toxic effects

Methodology Applied

Scientific EffectReceptor blocking:

Data Source

PatentUS12594330B2Anti-opioid compounds and methods of making and using same

Publication Date: 2026.04.07 HENNEPIN HEALTHCARE RESEARCH INSTITUTE

AI summary

This disclosure describes opioid-specific monoclonal antibodies (mAb), methods of making those antibodies, and methods of using those antibodies. The methods include, for example, treating a subject with an opioid use disorder or neonatal opioid withdrawal syndrome or preventing and reversing opioid overdose in a subject. Additionally or alternatively, the antibodies may be used to detect opioids including, for example, in a screening, diagnostic, or forensic assay.